Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies

NCT04395079 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04395079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04395079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 7, 2020
Completion date
October 11, 2026
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant female reproductive system neoplasm, platinum-resistant malignant female reproductive system neoplasm, recurrent malignant female reproductive system neoplasm, refractory malignant female reproductive system neoplasm